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Abstract
Background and Aims: The Roadmap concept is a therapeutic framework in chronic hepatitis B for the intensification of
nucleoside analogue monotherapy based on early virologic response. The efficacy and safety of this approach applied to
telbivudine treatment has not been investigated.
Methods: A multinational, phase IV, single-arm open-label study (ClinicalTrials.gov ID NCT00651209) was undertaken in
HBeAg-positive, nucleoside-naive adult patients with chronic hepatitis B. Patients received telbivudine (600 mg once-daily)
for 24 weeks, after which those with undetectable serum HBV DNA (,300 copies/mL) continued to receive telbivudine
alone while those with detectable DNA received telbivudine plus tenofovir (300 mg once-daily). Outcomes were assessed at
Week 52.
Results: 105 patients commenced telbivudine monotherapy, of whom 100 were included in the efficacy analysis. Fifty-five
(55%) had undetectable HBV DNA at Week 24 and continued telbivudine monotherapy; 45 (45%) received tenofovir
intensification. At Week 52, the overall proportion of undetectable HBV DNA was 93% (93/100) by last-observation-carried-
forward analysis (100% monotherapy group, 84% intensification group) and no virologic breakthroughs had occurred. ALT
normalization occurred in 77% (87% monotherapy, 64% intensification), HBeAg clearance in 43% (65% monotherapy, 16%
intensification), and HBeAg seroconversion in 39% (62% monotherapy, 11% intensification). Six patients had HBsAg
clearance. Myalgia was more common in the monotherapy group (19% versus 7%). No decrease in the mean glomerular
filtration rate occurred in either treatment group at Week 52.
Conclusions: Telbivudine therapy with tenofovir intensification at Week 24, where indicated by the Roadmap strategy,
appears effective and well tolerated for the treatment of chronic hepatitis B.
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There are approximately 400 million people worldwide who are
chronically infected with hepatitis B virus (HBV), of whom 75%
live in the Asia-Pacific region. Chronic hepatitis B results in liver
disease progressing to cirrhosis and hepatocellular carcinoma
(HCC) and is responsible for approximately one million liver-
related deaths per annum [1].
Treatment of HBV involves finite administration of pegylated
or unpegylated interferon alfa, or indefinite administration of
anti-HBV nucleoside/nucleotide analogues. Five such analogues
are currently available. Lamivudine, a deoxycytidine analogue,
was the first nucleoside approved for use in HBV and
lamivudine monotherapy remains common despite high rates
of treatment-emergent drug resistance [2]. Entecavir is a
deoxyguanosine analogue with a high genetic barrier to
resistance in treatment-naive patients [3]. However, lamivudine
resistance predisposes HBV to subsequent entecavir resistance
[4]. Telbivudine is an L-deoxythymidine analogue with superior
efficacy to lamivudine [5] but a similar resistance profile [6].
Finally, the nucleotides adefovir and tenofovir are both acyclic
mimetics of deoxyadenosine monophosphate which retain
activity against lamivudine- and telbivudine-resistant HBV [6].
However, adefovir is associated with dose-dependent nephro-
toxicity which restricts its dosing to 10 mg daily [7], at which
dose it demonstrates inferior virologic efficacy to the other
agents [8–10]. There are also concerns about the long-term
safety of tenofovir, which is associated with significant loss of
renal function in HIV treatment [11].
HBV viral replication is a key driver for disease progression
and is associated with the development of cirrhosis and HCC
[12]. The initial goal of treatment is to suppress viral
replication; thereafter, sustained (on-treatment) or maintained
(off-treatment) suppression of circulating HBV DNA is associ-
ated with improved serological responses and long-term
outcomes [13,14]. The emergence of drug-resistant HBV results
in breakthrough viremia leading to hepatitis and liver disease
progression. To ensure good long-term outcomes, the conser-
vation of HBV DNA suppression is essential.
Early virologic response, particularly at Week 24, is associated
with better long-term outcomes in chronic HBV, while detectable
HBV DNA at Week 24 is associated with a higher incidence of on-
therapy drug resistance [14,15]. This predictive association has
lead an international group of experts to propose the so-called
‘‘Roadmap’’ concept – a therapeutic algorithm for the conditional
intensification of nucleoside monotherapy based on early virologic
response [16]. In the Roadmap, monotherapy is continued if
plasma virus is undetectable (HBV DNA ,300 copies/mL) at
Week 24; while for those with detectable HBV DNA defined
options exist for either intensification or continued monotherapy.
The Roadmap principle is widely accepted in clinical practice
[17], but has yet to be prospectively evaluated. In this study, we
sought to confirm prospectively the clinical utility of the Roadmap
by investigating whether the conditional intensification of
telbivudine monotherapy with tenofovir, when indicated by the
algorithm, results in effective virologic suppression in nucleoside-
naive, HBeAg-positive patients with chronic hepatitis B. We
present 52-week primary efficacy and safety data.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethics Statement
Written informed consent was obtained and eligibility assessed
at a screening visit up to 6 weeks before the first dose of
telbivudine. The study was approved by the institutional review
boards/independent ethics committees of each study center and
was conducted in compliance with the principles of the
Declaration of Helsinki and in compliance with all International
Conference on Harmonization Good Clinical Practice Guidelines
and local regulatory requirements.
Patients
This study (ClinicalTrials.gov ID NCT00651209) had a
multinational, single-arm, open-label design. Male and female
adults ($18 years) were recruited between April 2008 and
September 2009 from 17 clinical centers in Argentina (n=3),
Brazil (4), China [Hong Kong] (2), Germany (4) and Thailand (4).
Major inclusion criteria were: documented chronic hepatitis B
with detectable HBsAg at screening and for at least 6 months
prior; HBeAg-positive (HBeAg+) and HBeAb-negative at screen-
ing; serum HBV DNA $5 log10 copies/mL by COBAS Amplicor
HBV Monitor
H assay (Roche Molecular Systems Inc., Pleasanton,
California); screening alanine aminotransferase (ALT) between
1.36and 106the upper limit of normal (ULN) with evidence of
chronic liver inflammation ($2 elevated ALT or aspartate
aminotransferase values over at least 6 months). Exclusion criteria
included: co-infection with hepatitis C virus, hepatitis D virus or
HIV; hepatic decompensation; any prior nucleoside treatment or
interferon/immunomodulator treatment in the 6 months before
screening, or chronic renal insufficiency or serum creatinine
clearance below 50 mL/min.
Study Design
Patient disposition is shown in Figure 1 and the study design in
Figure 2. Total treatment period is 104 weeks with the primary
analysis at 52 weeks. Planned study visits occurred at Weeks 2, 4,
8, 12, 16, 24, 26, 30, 40, 48, and 52. All patients received oral
telbivudine (600 mg once daily) for the first 24 weeks. At Week 26,
patients with detectable HBV DNA at Week 24 ($300 copies/mL
by COBAS Amplicor) received tenofovir disoproxil fumarate
(300 mg once daily) in addition to telbivudine throughout the
remaining time on study. Patients with undetectable HBV DNA
(,300 copies/mL) at Week 24 continued to receive telbivudine
monotherapy.
Efficacy and Safety Analyses
The primary efficacy endpoint was the proportion of patients
with undetectable HBV DNA at Week 52. Secondary endpoints
included the rate of virological breakthrough; HBV DNA
reductions from baseline and proportions with undetectable
HBV DNA at each study visit; ALT normalization rates at Weeks
24 and 52, and rates of HBeAg and HBsAg loss and seroconver-
sion at Week 52.
Clinical and laboratory adverse events were graded according to
pre-specified criteria and reported relationship to study drug was
at investigator discretion. ALT flares were defined according to
AASLD criteria [18]. Glomerular filtration rates (GFR) at each
visit were estimated using both the Cockcroft-Gault [19] and the
Modification Of Diet In Renal Disease Study (MDRD) equations
[20,21].
Statistical Analysis
The primary efficacy endpoint was analyzed as a binary
variable using last-observation-carried-forward (LOCF) imputa-
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were summarized at each visit, with the 95% confidence interval
calculated using the normal approximation method for binomial
proportion. Differences in baseline demographics and disease
characteristics between patients who remained on telbivudine
monotherapy through Week 52 and those who added tenofovir
after Week 24 were assessed for significance using Fisher’s exact
test for categorical variables and two-sided t-tests for continuous
variables. Changes from baseline in GFR at Week 52 were
assessed for significance using two-sided, paired t-tests. Statistical
analyses were carried out using SAS ver 1.3 (SAS Institute, Inc.
Carey, NC, USA).
The full intention-to-treat (ITT) population comprised all
patients who received at least one dose of telbivudine. As this
was a study of a specific therapeutic algorithm, a per-protocol
population was derived for efficacy assessments – i.e. the efficacy
population – which excluded one patient with a confirmed
baseline rtM204I resistance mutation to telbivudine/lamivudine, 2
patients lost to follow-up before Week 24, and 2 protocol violators
who did not receive tenofovir despite detectable Week 24 HBV
DNA. The safety population for adverse event monitoring
comprised the full ITT population as defined.
This was a single-arm study, hence the sample size was not
based on power for statistical comparison between treatment
groups. The primary objective was to demonstrate antiviral
efficacy by estimating the proportion of patients with HBV
DNA ,300 copies/mL at Week 52.
Based on the pivotal phase III GLOBE study (NCT00057265)
[15], approximately 44% of patients treated with telbivudine were
anticipated to have HBV DNA ,300 copies/mL at Week 24, of
whom 95% would still be ,300 copies/mL at Week 52. By
contrast, it was assumed from GLOBE data that only 34% of
patients with HBV DNA of 300 copies/mL or above at Week 24
would fall to below 300 copies/mL by Week 52 on telbivudine
monotherapy, giving an overall proportion of 60% with ,300
copies/mL at Week 52. It was assumed that adding tenofovir at
Week 24 for those with $300 HBV DNA copies/mL would
increase the proportion who subsequently fell to ,300 copies/mL
at Week 52 to at least 50%. With 100 patients, and under these
assumptions, the estimated 95% confidence interval was 70%
69%, which gave over 95% chance to show a higher rate of HBV
DNA ,300 copies/mL over telbivudine mono therapy in GLOBE
and also provided a reasonably accurate estimate. However, it
remains important to note that the two groups after Week 24–
telbivudine and telbivudine plus tenofovir – were not randomized
and hence statistical comparisons are limited. In particular, the
lack of randomization, and confounding by Week 24 response to
telbivudine, precludes efficacy comparison between the telbivudine
and telbivudine plus tenofovir groups.
Results
Patient Disposition
The efficacy population comprised 100 patients and the safety
population 105 patients (Figure 2).
Patient demographics and baseline characteristics are shown in
Table 1, stratified according to treatment after Week 24.
Compared with those who remained on telbivudine monotherapy,
a higher proportion of intensification patients had baseline HBV
DNA $9 log10 copies/mL (73.3% versus 36.4% of those
remaining on monotherapy; P,0.001). Mean baseline ALT was
also higher in those who remained on monotherapy (167.2 U/L
Figure 1. Patient disposition.
doi:10.1371/journal.pone.0054279.g001
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similar between those who did and did not receive intensification.
A total of 99/100 patients in the efficacy population (99%)
completed Week 52. There was one discontinuation in the
telbivudine plus tenofovir group for loss to follow-up after Week
30.
Efficacy
At Week 24, 55 of 100 patients (55%) in the efficacy population
had undetectable HBV DNA and continued to receive mono-
therapy. All of these 55 patients remained undetectable at Week
52 on telbivudine monotherapy. The remaining 45 patients (45%)
received telbivudine plus tenofovir after Week 24, of whom 38
(84.4%) had undetectable DNA at Week 52. Of these 45 patients,
12 had baseline HBV DNA ,9 log10 copies/mL (of whom 3 also
had baseline ALT $26ULN) and 33 had $9 log10 copies/mL. All
(12/12) of the patients with baseline HBV DNA ,9 log10 copies/
mL, and 78.8% (26/33) of those with $9 log10 copies/mL,
achieved undetectable DNA at week 52.
The overall rate of undetectable HBV DNA at Week 52
(primary endpoint) was therefore 93% (93/100) by LOCF analysis.
This value was the same by a strict ITT missing=failure analysis,
as one patient lost to follow-up after Week 30 had detectable HBV
DNA (2.67 log) at last visit.
Primary and secondary efficacy endpoints are shown in Table 2.
Figure 3 shows mean changes from baseline in HBV DNA by visit
for the two treatment groups. By LOCF analysis, mean reduction
from baseline in HBV DNA at Week 24 was 26.2 log10 copies/
mL in patients who continued to receive telbivudine alone, versus
26.0 log10 copies/mL in those who subsequently received
tenofovir. The Week 24 mean reduction remained stable at
26.2 log10 through Week 52 in those who continued telbivudine
monotherapy, while the addition of tenofovir resulted in an
additional 1.4 log10 reduction at Week 52 in the intensification
group.
Figure 2. Study design.
doi:10.1371/journal.pone.0054279.g002
Table 1. Demographics and baseline characteristics (efficacy population) according to post-Week 24 treatment.
Characteristic Telbivudine Telbivudine+tenofovir P value Overall
N5 5 4 5 1 0 0
Age, mean (SD) y 37 (10.4) 40 (15.0) 0.2394 38 (12.7)
Male, n (%) 37 (67) 30 (67) 1.0000 67 (67)
Weight, mean (SD) kg 69.7 (15.0) 65.5 (13.5) 0.1419 67.8 (14.4)
Race, n (%) Caucasian 11 (20) 16 (36) 0.0550 27 (27)
Black 0 1 (2) 1 (1)
Asian 41 (75) 28 (62) 69 (69)
Other 3 (6) 0 3 (3)
HBV genotype, n (%) A 6 (11) 8 (18) 0.2192 14 (14)
B 5 (9) 6 (13) 11 (11)
C 35 (64) 22 (49) 57 (57)
D 1 (2) 5 (11) 6 (6)
F 7 (13) 3 (7) 10 (10)
Intermediate 1 (2) 1 (2) 2 (2)
Serum ALT, mean (SD) U/L 167.2 (162.2) 93.2 (57.8) 0.0045 133.9 (131.2)
Serum HBV DNA (copies/mL), n (%) 5– ,6l o g 10 4 (7) 1 (2) 5 (5)
6– ,7l o g 10 7 (13) 1 (2) 8 (8)
7– ,8l o g 10 11 (20) 4 (9) 15 (15)
8– ,9l o g 10 13 (24) 6 (13) 19 (19)
$9l o g 10 20 (36) 33 (73) ,0.001 53 (53)
GFR, mean (SD) mL/min/1.73 m
2 by MDRD 93.4 (15.1) 92.1 (18.5) 0.6873 92.8 (16.6)
doi:10.1371/journal.pone.0054279.t001
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52 lost HBeAg and 39.4% (39/99) achieved HBeAg seroconver-
sion. Rates of HBeAg loss and seroconversion among those who
remained on monotherapy (65.5% and 61.8%, respectively) were
approximately fourfold higher than among those who received
intensification (15.9% and 11.4%, respectively). HBsAg clearance
at Week 52 occurred in 6.1% (6/99) and HBsAg seroconversion in
3.0% (3/99). Of the six patients with HBsAg loss, one (Genotype
B) was in the monotherapy group and five (3 Genotype A, 1 F;1 B)
in the intensification group; four were Hispanic Caucasians and
two were other races, and all had baseline HBV DNA .9 log10
copies/mL.
Overall, 77% of patients achieved ALT normalization at Week
52: 48/55 (87%) in the monotherapy group and 29/45 (64%) in
the intensification group.
No virologic breakthrough and no genotypic resistance over 52
weeks was observed.
Safety
Adverse events through Week 52 in the safety population are
shown in Table 3. Adverse events were similar to the GLOBE
study and balanced between treatment groups.
There were no deaths. Five serious adverse events occurred,
comprising one case each of atrial septal defect, gallbladder polyp,
vascular injury and spontaneous abortion on telbivudine alone;
and one foot fracture on telbivudine plus tenofovir. No event was
considered treatment related.
There were no reports of myopathy, myositis, rhabdomyolysis,
lactic acidosis, pancreatitis or peripheral neuropathy. One patient
reported mild muscle weakness. The study treatment was
interrupted and patient followed up in-study. This patient (highest
creatine kinase 1866 IU/mL) did not have objective evidence of
decreased muscle strength or abnormal EMG or muscle biopsy
results. Myalgia occurred in 13 patients. Twelve were mild and
one was moderate. Twelve resolved and one was followed up in-
study. Twelve patients continued the study treatment without
Table 2. Results of efficacy endpoints up to Week 52 (efficacy population, LOCF).
n (%) Efficacy endpoint
Telbivudine monotherapy
(n=55)
Telbivudine+Tenofovir
(n=45) Overall (N=100)
Week 24 HBV DNA ,300 copies/mL 55/55 (100) 0/45 55/100 (55.0)
Week 52 HBV DNA ,300 copies/mL 55/55 (100) 38/45 (84.4) 93/100 (93.0)
Virologic breakthrough 0/55 (0) 0/45 (0) 0/100 (0)
HBeAg loss* 36/55 (65.5) 7/44 (15.9) 43/99 (43.4)
HBeAg seroconversion* 34/55 (61.8) 5/44 (11.4) 39/99 (39.4)
HBsAg loss* 1/55 (1.8) 5/44 (11.4) 6/99 (6.1)
HBsAg seroconversion* 0/55 (0) 3/44 (6.8) 3/99 (3.0)
ALT normalization 48/55 (87.3) 29/45 (64.4) 77/100 (77.0)
*HBeAg/HBsAg loss and seroconversion were evaluated at Week 52 only without LOCF imputation. HBeAg/HBsAg data were unavailable for 1/45 patients receiving
telbivudine + tenofovir.
doi:10.1371/journal.pone.0054279.t002
Figure 3. Changes from baseline in HBV DNA by post-Week 24 treatment (efficacy population).
doi:10.1371/journal.pone.0054279.g003
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suspected to be related to study treatment.
Grade 3 or grade 4 creatine kinase elevations occurred in two
patients in the monotherapy group (one grade 3 at Week 48 and
one grade 4 at Week 49) and two intensification group patients
(one grade 3 at Week 16 on telbivudine alone and another at Week
52 on telbivudine plus tenofovir).
Two patients experienced an ALT flare. Both occurred under
initial telbivudine monotherapy (Weeks 4 and 8) in patients who
later received intensification. Both flare patients had undetectable
HBV DNA at Week 52.
There were no renal events other than one treatment-unrelated
case of moderate renal colic. No patient reported with creatinine
increase. Mean Week 52 GFR was significantly higher than
baseline in both treatment groups. Overall mean GFR change to
week 52 by the MDRD and the Cockcroft-Gault formulae was
6.9 mL/min and 8.3 mL/min, respectively, in the monotherapy
group; and 7.4 mL/min and 6.2 mL/min, respectively, in the
intensification group (P,0.01 for all comparisons). Figure 4 shows
week 52 GFR changes (MDRD) stratified by baseline GFR. No
significant GFR decline was noted in patients with low baseline
GFR, although numbers were small.
Discussion
In providing a framework for the conditional intensification of
monotherapy, the Roadmap [16] provides a rational approach to
improve long-term outcomes, while minimizing the risk of drug
resistance due to continued sub-optimal monotherapy or adverse
events associated with unnecessary combination treatment. Under
the Roadmap, nucleosides with a low genetic barrier to resistance
(e.g. lamivudine) are intensified with a non-cross-resistant second
agent if any HBV replication is still measurable at Week 24.
Although telbivudine is more potent than lamivudine with less on-
treatment resistance [5,15], it is closest to lamivudine in terms of
the features informing Roadmap decisions; and intensification was
applied to any patient with detectable Week 24 viremia. The
requirement for a non-cross-resistant second agent predicates the
use of adefovir or tenofovir [6], with tenofovir the better choice
due to greater potency [10].
Over half the patients achieved undetectable Week 24 viremia
on telbivudine alone, and, following tenofovir intensification of the
remaining 45%, the overall proportion of undetectable HBV DNA
was greater than 90% at Week 52. The additional reduction in
HBV DNA seen following tenofovir intensification of viremic
patients is presumably due to additive antiviral activity. There was
no in-study comparator to estimate the treatment effect of
tenofovir intensification over continued telbivudine monotherapy
in viremic patients. Nor was tenofovir monotherapy investigated,
or the effect of switching viremic patients to tenofovir as opposed
to adding it to telbivudine. However, historical data suggest that
intensification would have significantly improved Week 52
outcomes over what would have been seen had telbivudine
monotherapy been continued. In GLOBE [15] a broadly similar
rate of undetectable viremia at Week 24 (45%) was seen in
HBeAg+ telbivudine patients to that seen here (55%), but with a
substantially lower rate of undetectable DNA at Week 52 (60%).
GLOBE also showed lower rates of undetectable HBV DNA, ALT
normalization and HBeAg seroconversion at Week 52, and higher
rates of drug resistance at Week 48, for patients with detectable
Week 24 viremia [15], although the design of these analyses
precludes cross-study comparison. Similar results were observed in
a study of telbivudine versus lamivudine in over 300 Chinese
patients [22]. Finally, in the two-year GLOBE analyses, 82%
(166/203) of HBeAg+ patients with undetectable Week 24 HBV
remained undetectable through two years, but only 36% (89/247)
of those with detectable Week 24 DNA were undetectable at the
end of Year 2 [23].
Table 3. Most common ($5%) all-cause adverse events through Week 52 (safety population).
Tenofovir intensification (n=46)
n( % )
Telbivudine monotherapy
(n=59)
Telbivudine only
period
Tenofovir add on
period Overall*(N=105)
Total patients with any event 42 (71.2) 23 (50.0) 20 (43.5) 73 (69.5)
Myalgia 10 (16.9) 3 (6.5) 1 (2.2) 13 (12.4)
Headache 6 (10.2) 5 (10.9) 1 (2.2) 12 (11.4)
Upper respiratory tract infection 4 (6.8) 4 (8.7) 1 (2.2) 9 (8.6)
Dyspepsia 4 (6.8) 0 (0.0) 3 (6.5) 7 (6.7)
Arthralgia 1 (1.7) 2 (4.3) 3 (6.5) 5 (4.8)
Diarrhoea 3 (5.1) 1 (2.2) 1 (2.2) 5 (4.8)
Nausea 2 (3.4) 0 (0.0) 3 (6.5) 5 (4.8)
Dizziness 3 (5.1) 1 (2.2) 0 (0.0) 4 (3.8)
Fatigue 3 (5.1) 1 (2.2) 0 (0.0) 4 (3.8)
Pain in extremity 3 (5.1) 1 (2.2) 0 (0.0) 4 (3.8)
Pyrexia 3 (5.1) 1 (2.2) 0 (0.0) 4 (3.8)
Vomiting 1 (1.7) 0 (0.0) 3 (6.5) 4 (3.8)
Nasopharyngitis 3 (5.1) 0 (0.0) 1 (2.2) 4 (3.8)
Upper abdominal pain 0 (0.0) 3 (6.5) 0 (0.0) 3 (2.9)
Cough 0 (0.0) 2 (4.3) 1 (2.2) 3 (2.9)
*Intensification patients may have had an event during both the telbivudine only and intensification periods. Overall numbers with an indicated event may therefore be
less than the row total.
doi:10.1371/journal.pone.0054279.t003
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(Table 2), with most (approximately 85% of cases) occurring in
those with undetectable Week 24 viremia who remained on
telbivudine monotherapy. Effective clearance and seroconversion
of HBeAg therefore appears to be a function of early and complete
virologic suppression. The 6% rate of HBsAg loss at 1 year of
treatment was also substantially higher than the typically reported
per-annum rates of ,1% on nucleosides and approximately 3%
on interferon treatment [24,25]. The association of HBsAg
response with intensification (5/6 cases of loss and all three cases
of seroconversion) suggests a potential synergistic effect between
tenofovir and telbivudine that merits longer-term investigation in a
larger dataset.
Safety and tolerability were consistent with GLOBE, and, other
than myalgia, muscle-related events were rare. Of 13 patients with
myalgia, most (12/13) experienced mild events and most (12/13)
resolved sponataneously.
No renal toxicity was observed after 24 weeks of tenofovir plus
telbivudine. Mean GFR at week 52 was significantly higher than
baseline in both the monotherapy and intensification groups.
These findings are consistent with both 2-year clinical data from a
study of telbivudine versus lamivudine in decompensated HBV
disease [26]. Furthermore, retrospective analyses of seven studies
(2500 patients) in both compensated and decompensated disease
showed consistent GFR improvements on telbivudine treatment
for up to 6 years compared with GFR declines on lamivudine
therapy. Improvement was greatest in patients more than 50 years
old and those with abnormal baseline GFR; and was not
associated with baseline ascites, virologic response or reduction
in Child-Pugh score [27]. GFR improvement on telbivudine
stands in contrast to the declines over time observed in studies of
tenofovir [28] and entecavir [29]. Interestingly, GFR modeling
data from Mauss et al. predict a year-on-year GFR reduction of
approximately 2 mL/min in untreated HBV monoinfection which
is halved, but not abolished, by monotherapy with lamivudine,
adefovir, entecavir or tenofovir [30]. Telbivudine was not studied
in the Mauss model, and more research is needed to confirm and
provide a mechanism for the apparent dissimilarity of telbivudine
to the other nucleosides with respect to GFR preservation.
The Roadmap algorithm does not consider baseline HBV DNA
in treatment decisions [16]. However, in this study, high baseline
DNA was predictive of detectable Week 24 viremia requiring
intensification. Almost three-quarters of patients who received
tenofovir had baseline HBV DNA $9 log10 copies/mL. In future,
baseline viremia may need to be considered in any treatment
algorithm where decisions are made on the presence of detectable
viremia early on therapy.
In conclusion, telbivudine with conditional tenofovir intensifi-
cation according to the Roadmap algorithm was well tolerated
and, over 52 weeks, resulted in very high rates of undetectable
HBV DNA, ALT normalization, and HBeAg/HBsAg clearance
and seroconversion in nucleoside-naive HBeAg+ patients with
chronic HBV infection, along with an improvement in GFR. The
Roadmap appears to be a highly effective approach to HBV
treatment and 104-week data from this study are awaited.
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